<p>Oric Pharmaceuticals, Inc.（纳斯达克代码：ORIC - 获取免费报告）周三股价下跌 6.8%。该股最低交易价为 10.97 美元，最后交易价为 11.2850 美元。在午盘交易中，共成交 592,162 股，较平均交易量 1,798,275 股下降 67%。该股此前收盘价为 12.11 美元。</p>
<p>获取 <strong>Oric Pharmaceuticals</strong> 的提醒：</p>
<h2>分析师评级调整</h2>
<p>多位分析师对该公司发表了看法。Piper Sandler 在 1 月 7 日的研究报告中开始覆盖 Oric Pharmaceuticals，给予 “增持” 评级和 22.00 美元的目标价。华尔街 Zen 在 11 月 23 日的研究报告中将 Oric Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。摩根大通在 11 月 18 日的报告中将 Oric Pharmaceuticals 的目标价从 17.00 美元上调至 20.00 美元，并给予 “增持” 评级。富国银行在 12 月 8 日的研究报告中将 Oric Pharmaceuticals 的目标价从 19.00 美元上调至 25.00 美元，并给予 “增持” 评级。最后，Oppenheimer 在 11 月 14 日的研究报告中将 Oric Pharmaceuticals 的目标价从 12.00 美元上调至 15.00 美元，并给予该股 “跑赢大盘” 评级。共有 11 位研究分析师对该股给予 “买入” 评级，2 位给予 “持有” 评级，1 位给予 “卖出” 评级。根据 MarketBeat 的数据，该股的平均评级为 “适度买入”，平均目标价为 19.90 美元。</p>
<p><strong>查看我们关于 Oric Pharmaceuticals 的最新股票报告</strong></p>
<h2>Oric Pharmaceuticals 股价下跌 6.1%</h2>
<p>该公司的 50 日简单移动平均线为 10.10 美元，200 日简单移动平均线为 10.93 美元。该公司的市值为 11.1 亿美元，市盈率为-6.59，贝塔值为 1.36。</p>
<p>Oric Pharmaceuticals（纳斯达克代码：ORIC - 获取免费报告）最近在 11 月 13 日发布了季度财报。该公司报告每股收益（EPS）为-0.33 美元，超出市场共识预期的-0.41 美元，超出幅度为 0.08 美元。平均而言，卖方分析师预计 Oric Pharmaceuticals, Inc.在当前财年将发布-2.17 美元的每股收益。</p>
<h2>Oric Pharmaceuticals 的内部交易</h2>
<p>在其他消息中，首席执行官 Jacob Chacko 在 12 月 16 日的交易中出售了 33,374 股 Oric Pharmaceuticals 的股票。该股票以平均价格 9.06 美元出售，总价值为 302,368.44 美元。交易完成后，首席执行官持有 581,711 股公司股票，价值为 5,270,301.66 美元。此次交易使其持股减少了 5.43%。该交易已在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站获取。此外，内部人士 Pratik S. Multani 在 12 月 16 日的交易中出售了 10,720 股该公司的股票。该股票以平均价格 9.06 美元出售，总交易额为 97,123.20 美元。出售后，内部人士持有 68,149 股公司股票，价值约为 617,429.94 美元。这代表其持股减少了 13.59%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士共出售了 54,814 股公司股票，价值为 496,615 美元。内部人士持有公司股票的比例为 5.55%。</p>
<h2>机构资金流入和流出</h2>
<p>对该公司的持股情况，最近对冲基金进行了调整。Zurcher Kantonalbank Zurich Cantonalbank 在第四季度购买了 Oric Pharmaceuticals 的新股份，价值为 135,000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Oric Pharmaceuticals 的持股增加了 26.0%。Mirae Asset Global Investments Co. Ltd.现在拥有 4,732 股公司股票，价值 39,000 美元，此前在上个季度又购买了 977 股。Tema Etfs LLC 在第四季度购买了 Oric Pharmaceuticals 的新股份，价值约为 228,000 美元。Hennion &amp; Walsh Asset Management Inc.在第四季度将其在 Oric Pharmaceuticals 的持股增加了 15.7%。Hennion &amp; Walsh Asset Management Inc.现在拥有 170,072 股公司股票，价值 1,391,000 美元，此前在上个季度又购买了 23,024 股。最后，SG Americas Securities LLC 在第四季度将其在 Oric Pharmaceuticals 的持股增加了 127.6%。SG Americas Securities LLC 现在拥有 41,016 股公司股票，价值 336,000 美元，此前在该期间又购买了 22,993 股。对冲基金和其他机构投资者持有公司 95.05% 的股票。</p>
<h2>Oric Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Oric Pharmaceuticals, Inc.是一家总部位于加利福尼亚州南旧金山的临床阶段生物制药公司。该公司致力于发现和开发旨在克服实体肿瘤肿瘤学中耐药机制的小分子治疗药物。其研究工作重点是识别新靶点并推进精准医疗，以便在标准疗法失效时恢复或增强患者的反应。</p>
<p>该公司的产品管线包括主要候选药物 ORIC-101，这是一种选择性、口服可用的糖皮质激素受体拮抗剂，目前正在对获得化疗和激素药物耐药的实体肿瘤患者进行 1/2 期临床试验。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Oric Pharmaceuticals 更好</li>
<li>您的签名缺失 - 请在为时已晚之前采取行动</li>
<li>什么费用可以从资本利得税中扣除？</li>
<li>请勿删除，立即阅读</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>在周一上午 9:30 购买该股票！</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Oric Pharmaceuticals 吗？</h2>
<p>在考虑 Oric Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Oric Pharmaceuticals 并不在名单上。</p>
<p>虽然 Oric Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - SPDR

标普全球医疗股指数 ETF - iShares

<p>Oric Pharmaceuticals（纳斯达克代码：ORIC）股价下跌 6.8%，至 11.2850 美元，交易量下降 67%。分析师的评级意见不一，Piper Sandler 首次覆盖给予 “增持” 评级，目标价为 22 美元，而 Wall Street Zen 则下调至 “卖出”。该股票的平均评级为 “适度买入”，目标价为 19.90 美元。近期的内部销售和机构投资表明交易活跃。Oric Pharmaceuticals 专注于开发针对实体肿瘤的治疗药物，报告的季度每股收益为（-0.33 美元），超出预期</p>

<p>Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report)'s share price fell 6.8% on Wednesday . The stock traded as low as $10.97 and last traded at $11.2850. 592,162 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 1,798,275 shares. The stock had previously closed at $12.11.</p>
<div class="lb-trans"><p>Oric Pharmaceuticals, Inc.（纳斯达克代码：ORIC - 获取免费报告）周三股价下跌 6.8%。该股最低交易价为 10.97 美元，最后交易价为 11.2850 美元。在午盘交易中，共成交 592,162 股，较平均交易量 1,798,275 股下降 67%。该股此前收盘价为 12.11 美元。</p>
</div><p>Get <strong>Oric Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Oric Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several analysts have weighed in on the company. Piper Sandler initiated coverage on Oric Pharmaceuticals in a research report on Wednesday, January 7th. They issued an &#34;overweight&#34; rating and a $22.00 price objective for the company. Wall Street Zen cut shares of Oric Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Sunday, November 23rd. JPMorgan Chase &amp; Co. boosted their price target on Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, November 18th. Wells Fargo &amp; Company upped their price target on Oric Pharmaceuticals from $19.00 to $25.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, December 8th. Finally, Oppenheimer lifted their price objective on Oric Pharmaceuticals from $12.00 to $15.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, November 14th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $19.90.</p>
<div class="lb-trans"><p>多位分析师对该公司发表了看法。Piper Sandler 在 1 月 7 日的研究报告中开始覆盖 Oric Pharmaceuticals，给予 “增持” 评级和 22.00 美元的目标价。华尔街 Zen 在 11 月 23 日的研究报告中将 Oric Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。摩根大通在 11 月 18 日的报告中将 Oric Pharmaceuticals 的目标价从 17.00 美元上调至 20.00 美元，并给予 “增持” 评级。富国银行在 12 月 8 日的研究报告中将 Oric Pharmaceuticals 的目标价从 19.00 美元上调至 25.00 美元，并给予 “增持” 评级。最后，Oppenheimer 在 11 月 14 日的研究报告中将 Oric Pharmaceuticals 的目标价从 12.00 美元上调至 15.00 美元，并给予该股 “跑赢大盘” 评级。共有 11 位研究分析师对该股给予 “买入” 评级，2 位给予 “持有” 评级，1 位给予 “卖出” 评级。根据 MarketBeat 的数据，该股的平均评级为 “适度买入”，平均目标价为 19.90 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Oric Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Oric Pharmaceuticals 的最新股票报告</strong></p>
</div><h2>Oric Pharmaceuticals Stock Down 6.1%</h2>
<div class="lb-trans"><h2>Oric Pharmaceuticals 股价下跌 6.1%</h2>
</div><p>The business has a fifty day simple moving average of $10.10 and a 200-day simple moving average of $10.93. The firm has a market cap of $1.11 billion, a P/E ratio of -6.59 and a beta of 1.36.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 10.10 美元，200 日简单移动平均线为 10.93 美元。该公司的市值为 11.1 亿美元，市盈率为-6.59，贝塔值为 1.36。</p>
</div><p>Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.08. On average, sell-side analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Oric Pharmaceuticals（纳斯达克代码：ORIC - 获取免费报告）最近在 11 月 13 日发布了季度财报。该公司报告每股收益（EPS）为-0.33 美元，超出市场共识预期的-0.41 美元，超出幅度为 0.08 美元。平均而言，卖方分析师预计 Oric Pharmaceuticals, Inc.在当前财年将发布-2.17 美元的每股收益。</p>
</div><h2>Insider Transactions at Oric Pharmaceuticals</h2>
<div class="lb-trans"><h2>Oric Pharmaceuticals 的内部交易</h2>
</div><p>In other news, CEO Jacob Chacko sold 33,374 shares of Oric Pharmaceuticals stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $302,368.44. Following the completion of the transaction, the chief executive officer owned 581,711 shares of the company's stock, valued at $5,270,301.66. The trade was a 5.43% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, insider Pratik S. Multani sold 10,720 shares of the firm's stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20. Following the sale, the insider owned 68,149 shares of the company's stock, valued at approximately $617,429.94. This represents a 13.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 54,814 shares of company stock valued at $496,615. Insiders own 5.55% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 Jacob Chacko 在 12 月 16 日的交易中出售了 33,374 股 Oric Pharmaceuticals 的股票。该股票以平均价格 9.06 美元出售，总价值为 302,368.44 美元。交易完成后，首席执行官持有 581,711 股公司股票，价值为 5,270,301.66 美元。此次交易使其持股减少了 5.43%。该交易已在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站获取。此外，内部人士 Pratik S. Multani 在 12 月 16 日的交易中出售了 10,720 股该公司的股票。该股票以平均价格 9.06 美元出售，总交易额为 97,123.20 美元。出售后，内部人士持有 68,149 股公司股票，价值约为 617,429.94 美元。这代表其持股减少了 13.59%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士共出售了 54,814 股公司股票，价值为 496,615 美元。内部人士持有公司股票的比例为 5.55%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Oric Pharmaceuticals during the fourth quarter valued at $135,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Oric Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company's stock valued at $39,000 after purchasing an additional 977 shares during the last quarter. Tema Etfs LLC bought a new position in Oric Pharmaceuticals during the fourth quarter valued at approximately $228,000. Hennion &amp; Walsh Asset Management Inc. boosted its holdings in Oric Pharmaceuticals by 15.7% in the fourth quarter. Hennion &amp; Walsh Asset Management Inc. now owns 170,072 shares of the company's stock worth $1,391,000 after purchasing an additional 23,024 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in Oric Pharmaceuticals by 127.6% in the 4th quarter. SG Americas Securities LLC now owns 41,016 shares of the company's stock worth $336,000 after purchasing an additional 22,993 shares during the period. Hedge funds and other institutional investors own 95.05% of the company's stock.</p>
<div class="lb-trans"><p>对该公司的持股情况，最近对冲基金进行了调整。Zurcher Kantonalbank Zurich Cantonalbank 在第四季度购买了 Oric Pharmaceuticals 的新股份，价值为 135,000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Oric Pharmaceuticals 的持股增加了 26.0%。Mirae Asset Global Investments Co. Ltd.现在拥有 4,732 股公司股票，价值 39,000 美元，此前在上个季度又购买了 977 股。Tema Etfs LLC 在第四季度购买了 Oric Pharmaceuticals 的新股份，价值约为 228,000 美元。Hennion &amp; Walsh Asset Management Inc.在第四季度将其在 Oric Pharmaceuticals 的持股增加了 15.7%。Hennion &amp; Walsh Asset Management Inc.现在拥有 170,072 股公司股票，价值 1,391,000 美元，此前在上个季度又购买了 23,024 股。最后，SG Americas Securities LLC 在第四季度将其在 Oric Pharmaceuticals 的持股增加了 127.6%。SG Americas Securities LLC 现在拥有 41,016 股公司股票，价值 336,000 美元，此前在该期间又购买了 22,993 股。对冲基金和其他机构投资者持有公司 95.05% 的股票。</p>
</div><h2>Oric Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Oric Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.</p>
<div class="lb-trans"><p>Oric Pharmaceuticals, Inc.是一家总部位于加利福尼亚州南旧金山的临床阶段生物制药公司。该公司致力于发现和开发旨在克服实体肿瘤肿瘤学中耐药机制的小分子治疗药物。其研究工作重点是识别新靶点并推进精准医疗，以便在标准疗法失效时恢复或增强患者的反应。</p>
</div><p>The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.</p>
<div class="lb-trans"><p>该公司的产品管线包括主要候选药物 ORIC-101，这是一种选择性、口服可用的糖皮质激素受体拮抗剂，目前正在对获得化疗和激素药物耐药的实体肿瘤患者进行 1/2 期临床试验。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Oric Pharmaceuticals</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>What Expenses Can Be Deducted From Capital Gains Tax?</li>
<li>Do not delete, read immediately</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
<li>Buy This Stock at 9:30 AM on MONDAY!</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Oric Pharmaceuticals 更好</li>
<li>您的签名缺失 - 请在为时已晚之前采取行动</li>
<li>什么费用可以从资本利得税中扣除？</li>
<li>请勿删除，立即阅读</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>在周一上午 9:30 购买该股票！</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Oric Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Oric Pharmaceuticals 吗？</h2>
</div><p>Before you consider Oric Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Oric Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Oric Pharmaceuticals 并不在名单上。</p>
</div><p>While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Oric Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oric Pharmaceuticals (NASDAQ:ORIC)  Shares Down 6.8%   - Time to Sell?

Market Beat

ORIC Pharmaceuticals

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

美国制药 ETF - iShares

医疗业 ETF - Vanguard

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

基因改革 ETF - ARK

ORIC Pharmaceuticals（纳斯达克代码：ORIC）股价下跌 6.8% - 现在是卖出的时候吗？